Hueseyin
Hueseyin Cabuk, Waldkraiburg DE
Patent application number | Description | Published |
---|---|---|
20150252873 | ROTARY OSCILLATION DAMPER - The present invention relates to a rotary oscillation damper | 09-10-2015 |
Hueseyin Firat, Huningue FR
Patent application number | Description | Published |
---|---|---|
20100221186 | BIOMARKERS FOR CARDIOVASCULAR SIDE-EFFECTS INDUCED BY COX-2 INHIBITORY COMPOUNDS - Cardiovascular tissue mRNA expression profiles in monkeys treated with coxibs was analyzed. Genomic data indicated that the animals showing vasculitis exhibit a specific mRNA expression pattern. The pattern includes gene expression changes involved in blood and endothelial cell (EC) activation, interaction of blood cells with EC, activation of INFγ pathway, and release of pro-inflammatory cytokines and chemo-attractants. These results provide direct evidence of minimal vasculitis together with corresponding genomic signature and peripheral biomarkers for minimal vasculatis. These results also suggest that treatment might triggers/aggravate a clinically latent cardiovascular disorder in the context of an endothelium tropic viral infection and/or an autoimmune vascular disorder. The histopathological examination revealed marginal vascular changes consistent with the genomic findings. Measurement of soluble proteins present in serum and plasma using a multiplex assay were in line with the genomic results, showing the increased level of INFγ inducible proteins, increased expression of CXCL10 chemokine was confirmed by an ELISA both in serum and plasma. Use of these peripheral biomarkers allows a safe usage of cox-2 inhibitory compounds in clinics and selection of cox-2 inhibitory follow-up compounds with no cardiovascular toxicity. These data together with biochemical and histopathological findings suggest that the specific cox2 inhibitor may exaggerate host immune response during some specific viral infections with endothelial tropism, or subjacent vascular autoimmune disorders. | 09-02-2010 |
20150152501 | BIOMARKERS FOR CARDIOVASCULAR SIDE-EFFECTS INDUCED BY COX-2 INHIBITORY COMPOUNDS - The present invention is directed to methods for detecting the presence of minimal or early vasculitis or other vasculopathies induced by a cox-2 inhibitor in a subject to whom a cox-2 inhibitor has been administered, selection of cox-2 inhibitory compounds, use of a cox-2 inhibitory compounds in the manufacture of anti-inflammatory medicaments, and vaccination strategies. | 06-04-2015 |
Hueseyin Haybat, Ilvesheim DE
Patent application number | Description | Published |
---|---|---|
20100070946 | Providing Supplier Relationship Management Software Application as Enterprise Services - Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having supplier relationship management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described. | 03-18-2010 |
Hueseyin Haybat, Mannheim DE
Patent application number | Description | Published |
---|---|---|
20120173384 | PROVIDING SUPPLIER RELATIONSHIP MANAGEMENT SOFTWARE APPLICATION AS ENTERPRISE SERVICES - Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having supplier relationship management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described. | 07-05-2012 |
Hueseyin Sirma, Elmshorn DE
Patent application number | Description | Published |
---|---|---|
20140031309 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to ss-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said ss-f31 L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said ss-L-nucleoside and analogs. | 01-30-2014 |